International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review

被引：0

作者：

Matveev, V. B. ^{[1
]}

Khalmurzaev, O. A. ^{[1
]}

Evsyukova, O., I ^{[1
]}

机构：

[1] Minist Hlth Russia, NN Blokhin Natl Med Res Ctr Oncol, 24 Kashirskoe Shosse, Moscow 115478, Russia

来源：

ONKOUROLOGIYA | 2020年 / 16卷 / 04期

关键词：

prostate cancer; HRR mutations; BRCA; olaparib; DNA-REPAIR;

D O I：

10.17650/1726-9776-2020-16-4-197-206

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The following review presents a problem of metastatic castration-resistant prostate cancer and its association with germline or somatic mutations in homologous recombination repair (HRR). In 2020, olaparib was approved in the Russian Federation as a monotherapy for metastatic castration-resistant prostate cancer with germline or somatic mutations of genes involved in DNA repair by homologous recombination, after progression on therapy with new hormonal drugs. We describe a review of the main olaparib clinical trials assessing its efficacy, safety and tolerance in metastatic castration-resistant prostate cancer patients.

引用

页码：197 / 206

页数：10

共 50 条

[41] The role of abiraterone in the management of metastatic castration-resistant prostate cancer
Rawlinson, Alex
Mohammed, Aza
Beatty, John
Bell, Richard
Miller, Marek
EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (04) : 429 - 437
[42] Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Chi, Kim N.
Rathkopf, Dana
Smith, Matthew R.
Efstathiou, Eleni
Attard, Gerhardt
Olmos, David
Lee, Ji Youl
Small, Eric J.
Gomes, Andrea J. Pereira De Santana
Roubaud, Guilhem
Saad, Marniza
Zurawski, Bogdan
Sakalo, Valerii
Mason, Gary E.
Francis, Peter
Ms, George Wang
Wu, Daphne
Diorio, Brooke
Lopez-Gitlitz, Angela
Sandhu, Shahneen
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3339 - +
[43] Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer
Pobel, Cedric
Auclin, Edouard
Teyssonneau, Diego
Laguerre, Brigitte
Cancel, Mathilde
Boughalem, Elouen
Noel, Johanna
Brachet, Pierre Emmanuel
Maillet, Denis
Barthelemy, Philippe
Helissey, Carole
Thibault, Constance
Oudard, Stephane
CANCER MEDICINE, 2021, 10 (18): : 6304 - 6309
[44] Prevalence of Measurable Disease in Metastatic Castration-resistant Prostate Cancer
Sonpavde, Guru
Madan, Ankit
Baker, Mary K.
May, Jori E.
Naik, Gurudatta
Bae, Sejong
CLINICAL GENITOURINARY CANCER, 2017, 15 (05) : 534 - 539
[45] Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
Ma, Yi
He, Lijie
Huang, Qianwen
Zheng, Shuang
Zhang, Zhiqiang
Li, Hongshi
Liu, Shuang
BMC MEDICAL GENETICS, 2018, 19
[46] Circulating tumor cells in metastatic castration-resistant prostate cancer
Brian I. Rini
Current Oncology Reports, 2009, 11 : 163 - 164
[47] Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
El-Amm, Joelle
Aragon-Ching, Jeanny B.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2016, 10 : 11 - 19
[48] Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review
Francini, Edoardo
Agarwal, Neeraj
Castro, Elena
Cheng, Heather H.
Chi, Kim N.
Clarke, Noel
Mateo, Joaquin
Rathkopf, Dana
Saad, Fred
Tombal, Bertrand
EUROPEAN UROLOGY, 2025, 87 (01) : 29 - 46
[49] Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer
Chau, Vincent
Madan, Ravi A.
Figg, William D.
CANCER BIOLOGY & THERAPY, 2020, 21 (10) : 884 - 887
[50] Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
Jang, Albert
Sartor, Oliver
Barata, Pedro C.
Paller, Channing J.
CANCERS, 2020, 12 (11) : 1 - 14

← 1 2 3 4 5 →